Navid Ahmadi1, Kan Gao2, Noel Chia2, Min Sung Kwon3, Carsten E Palme4, Ruta Gupta5, Jonathan Clark4. 1. Concord Hospital, Sydney, New South Wales, Australia; Faculty of Medicine, University of New South Wales, Sydney, New South Wales, Australia. Electronic address: Dr.ahmadi.navid@gmail.com. 2. Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Sydney, New South Wales, Australia. 3. Central Clinical School, University of Sydney, Sydney, New South Wales, Australia. 4. Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Sydney, New South Wales, Australia; Central Clinical School, University of Sydney, Sydney, New South Wales, Australia; Department of Head and Neck Surgery, Chris O'Brien Lifehouse, Sydney, New South Wales, Australia. 5. Sydney Head and Neck Cancer Institute, Chris O'Brien Lifehouse, Sydney, New South Wales, Australia; Central Clinical School, University of Sydney, Sydney, New South Wales, Australia; Department of Tissue Pathology and Diagnostic Oncology, Royal Prince Alfred Hospital, Sydney, New South Wales, Australia.
Abstract
OBJECTIVES: The aim of this study was to investigate the association between oral cavity squamous cell carcinoma (OSCC) and PD-L1 expression, and smoking, and p53 expression. STUDY DESIGN: Histologic review of archival slides of patients with OSCC, obtained from the Sydney Head and Neck Cancer Institute database from 1995 to 2015, was undertaken with tissue microarray construction and immunohistochemistry to identify PD-L1 and p53 expression. RESULTS: Of the 255 patients identified, PD-L1 expression was observed in 70 (27.5%) and more commonly in females (odds ratio [OR] = 2.19; P = .005). PD-L1 expression of 1% or greater was associated with p53 expression (P = .019) and associated with absence of smoking (P = .06). PD-L1 expression, at 1%, was not significantly associated with overall survival (P = .482), disease-specific survival (P = .864), and disease-free survival (P = .731). CONCLUSIONS: Our data demonstrate that PD-L1 expression of 1% or greater is more frequent in OSCC in females, nonsmokers, and in patients with p53-positive OSCC. These findings have important implications for immune therapy for OSCC.
OBJECTIVES: The aim of this study was to investigate the association between oral cavity squamous cell carcinoma (OSCC) and PD-L1 expression, and smoking, and p53 expression. STUDY DESIGN: Histologic review of archival slides of patients with OSCC, obtained from the Sydney Head and Neck Cancer Institute database from 1995 to 2015, was undertaken with tissue microarray construction and immunohistochemistry to identify PD-L1 and p53 expression. RESULTS: Of the 255 patients identified, PD-L1 expression was observed in 70 (27.5%) and more commonly in females (odds ratio [OR] = 2.19; P = .005). PD-L1 expression of 1% or greater was associated with p53 expression (P = .019) and associated with absence of smoking (P = .06). PD-L1 expression, at 1%, was not significantly associated with overall survival (P = .482), disease-specific survival (P = .864), and disease-free survival (P = .731). CONCLUSIONS: Our data demonstrate that PD-L1 expression of 1% or greater is more frequent in OSCC in females, nonsmokers, and in patients with p53-positive OSCC. These findings have important implications for immune therapy for OSCC.
Authors: Maurice van Duijvenvoorde; Sarah Derks; Idris Bahce; C René Leemans; Rieneke van de Ven; Marieke F Fransen Journal: Clin Transl Immunology Date: 2022-01-10
Authors: Juan Francisco Peña-Cardelles; José Juan Pozo-Kreilinger; Giovanna Roncador; Jesús Esteban-Hernández; José Ernesto Moro-Rodríguez; Ana Sastre-Perona; Beatriz Castelo-Fernández; José Luis Cebrián-Carretero Journal: Biomedicines Date: 2022-03-19